TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02805855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Adipose-Derived Mesenchymal Stromal Cells
Description: Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices (cGMPs).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Adipose-Derived Mesenchymal Stromal Cells
Description: Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices (cGMPs).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Adipose-Derived Mesenchymal Stromal Cells
Description: Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices (cGMPs).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Adipose-Derived Mesenchymal Stromal Cells
Description: Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices (cGMPs).
Study: NCT00887926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-EB10
Description: Cohort 1 will receive IMC-EB10 intravenously for 3 weekly infusions, followed by a 1-week observation period. The starting dose in Cohort 1 will be 5 mg/kg. After all participants in Cohort 1 complete the first cycle of therapy, dose escalation for subsequent cohorts will proceed as follows: Cohort 2 - 10 mg/kg, Cohort 3 - 20 mg/kg, Cohort 4 - 30 mg/kg. Participants who experience a dose-limiting toxicity (DLT) will not receive further IMC-EB10 treatment, but will continue to be followed on the protocol. Participants may continue to receive IMC-EB10 therapy, in the absence of treatment failure, treatment intolerance, or other withdrawal criteria for additional 28-day cycles at the same dose that they initially received. Dosing for Cycle 2 and beyond will be administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle
Study: NCT01561742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline will be given orally at 200 mg a day for 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: EquivalentPlacebo will be given
Study: NCT02461940

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adolescent Behavioral Intervention
Description: Session 1 focuses on STI/HIV education and self-reflection. Session 2 aims to increase the awareness of STI/HIV preventive strategies by instilling condom use and negotiation skills. Motivational Interviewing is used during the behavioural counselling. Session 3 reviews the goal on safer sex set by the participant and examines the successful strategies on safer sex and identifies triggers for relapse. Success stories are shared to renew their motivation. Session 4 reinforces the progress of the participant by recapitulating the knowledge and motivation explored in previous sessions. The online sessions, by phone/SMS/Whatsapp are conducted 2 months after the second and third sessions to find out if they face any difficulties and to reinforce prevention information covered previously.
Study: NCT03370224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory retraining exercises
Description: Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control memory exercises
Description: Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
Study: NCT00771771

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early supported discharge with day unit rehabilitation
Description: Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in a day unit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early supported discharge with home rehabilitation
Description: Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in the patient's home
Study: NCT01444846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005 Low dose
Description: Oral capsules, 200 mg ebselen, twice daily, 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005 Middle dose
Description: Oral capsules, 400 mg ebselen, twice daily, 4 days
Study: NCT03596645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants receive subcutaneous (SC) golimumab through Week 50, where doses will be based on body surface area. After the Week 54 evaluations, at the discretion of investigator, participants benefiting from continued SC golimumab will continue to receive SC golimumab in the extension until end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
Study: NCT02816853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: Domperidone 10 mg or 20 mg tablets will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: Domperidone 10 mg or 20 mg tablets will be administered.
Study: NCT01444846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005 High dose
Description: Oral capsules, 600 mg ebselen, twice daily, 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules, 0 mg ebselen, twice daily, 4 days
Study: NCT02816853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: Domperidone 10 mg or 20 mg tablets will be administered.
Study: NCT03629353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal intubation
Description: After preoxygenation with FiO2 1.0 and flow rate of 8 L/min for 3 minutes, the enrolled patients will be intubated with endotracheal tube and maintained oxygenation during surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: After preoxygenation with 100% oxygen through high flow nasal cannula for 3 minutes, the enrolled patients will be maintained intubationless oxygenation with flow rate of 70 L/min during surgery.
Study: NCT02663830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil & clomiphene citrate
Description: 105 Patients will receive 25 mg sildenafil citrate 6hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene only
Description: 105 Patients will receive clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
Study: NCT03746717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: occlusive wound closure
Description: skin closure with a commercially available wound closure product consisting of a synthetic adhesive mesh and cyanoacrylate based skin glue

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional wound closure
Description: wound closure with surgical staples
Study: NCT01625000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214 3mg
Description: Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.
Study: NCT02816853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: Domperidone 10 mg or 20 mg tablets will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.
Study: NCT01625000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214 6mg
Description: Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214 9mg
Description: Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone 4mg
Description: Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.
Study: NCT03078855

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: vitamin D3 2,000 IU daily

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Administered weekly x 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered weekly x 4
Study: NCT02816853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.
Study: NCT03078855

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: methylcellulose
Study: NCT00147121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab + Standard CHOP
Description: Rituximab + Standard CHOP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab + Bi-weekly CHOP
Description: Rituximab + Bi-weekly CHOP
Study: NCT02816853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg tablet will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg tablet will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg tablet will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg tablet will be administered.
Study: NCT02118493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Benign Biliary Stenosis, Laser
Description: Single use of laser to attempt excision of biliary ductal tissue causing stenosis.
Study: NCT02033642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Behavioral Intervention
Description: Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to: (1) educate adolescent/young adult participants and their parents in principles of good nutrition and physical activity, and (2) train parents to implement lifestyle changes at home to facilitate weight loss in their child by monitoring diet and physical activity behaviors, setting goals, providing support and reinforcement, and assessing and making changes to the home environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintenance
Description: The Maintenance condition in this study is a 12-session intervention designed to extend FBBI and continue to teach adolescent/young adult participants and their parents to continue practicing lifestyle behaviors, generalize healthful behaviors to new environments, find additional social and community supports, and prevent and manage relapse.
Study: NCT04679064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: PARP-inihibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: PD-1 inihibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: Chemotherapy drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Chemotherapy drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Chemotherapy drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Chemotherapy drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Chemotherapy drug
Study: NCT00584428

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Dose Chemo with Autologous BMT
Description: Carboplatin/VP-16/Cytoxan for women 18-59 and Carboplatin/Thiotepa/Cytoxan for women 60-70
Study: NCT01411059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: yoga classes 2 times per week for 32 weeks
Study: NCT04474821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational materials on HPV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT02141360

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MRI Diagnostic
Description: Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Diagnostic
Description: Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
Study: NCT04396158

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radioactive iodine
Description: 80-200 mCi of radioactive iodine will be given to thyroid cancer patients
Study: NCT04456192

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Indoor Cycling Interval Exercise Training
Description: The 3-month intervention consisted of a physical exercise program involving three indoor cycling sessions per week, with a total of 36 training sessions. Subjects exercised on cycle ergometers Schwinn® Evolution® (Schwinn Bicycle Company, Boulder, Colorado, USA). Each session lasted approximately 55 minutes. Training sessions consisted of a 5-min low-intensity warm-up (cycling at 50-65% of maximum heart rate (HRmax)), 40 min of main training at an intensity of 65-95% of HRmax, 5 min of non-weight-bearing cycling, finishing with 5 min of low-intensity cool-down stretching and breathing exercises.~Main part of the training was interval. Each exercise session consisted of 3 to 4 high intensity intervals with intensity exceeding 80% of HRmax, often reaching anaerobic threshold. High intensity intervals lasted approximately 4-minutes and were interspersed by recovery periods at 65-80% of HRmax.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indoor Cycling Interval Exercise Training
Description: The 3-month intervention consisted of a physical exercise program involving three indoor cycling sessions per week, with a total of 36 training sessions. Subjects exercised on cycle ergometers Schwinn® Evolution® (Schwinn Bicycle Company, Boulder, Colorado, USA). Each session lasted approximately 55 minutes. Training sessions consisted of a 5-min low-intensity warm-up (cycling at 50-65% of maximum heart rate (HRmax)), 40 min of main training at an intensity of 65-95% of HRmax, 5 min of non-weight-bearing cycling, finishing with 5 min of low-intensity cool-down stretching and breathing exercises.~Main part of the training was interval. Each exercise session consisted of 3 to 4 high intensity intervals with intensity exceeding 80% of HRmax, often reaching anaerobic threshold. High intensity intervals lasted approximately 4-minutes and were interspersed by recovery periods at 65-80% of HRmax.
Study: NCT02293603

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Cardiosphere-Derived Cells (CDCs)
Description: Intracoronary delivery of CAP-1002 or placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Allogeneic Cardiosphere-Derived Cells (CDCs)
Description: Intracoronary delivery of CAP-1002 or placebo
Study: NCT01078389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Febuxostat
Description: Febuxostat placebo-matching capsules
Study: NCT01873027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI
Description: * OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI~* Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVUS
Description: * IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI~* Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI
Study: NCT03688464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
Study: NCT02161380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),
Description: injection of Total Volume of each intravitreal injection is 200 µL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)
Description: injection of Total Volume of each intravitreal injection is 200 µL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of scAAV2-P1ND4v2 2.4 X10e10vg (High)
Description: injection of Total Volume of each intravitreal injection is 100 µL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)
Description: injection of Total Volume of each intravitreal injection is 100 µL
Study: NCT02074839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120
Description: AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
Study: NCT03330639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Capsaicin is a homeopathic medication and there for this drug is not subject to the requirements of the FDA.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive the saline placebo solution.
Study: NCT01224366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03384641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline 200 mg
Description: Participants will receive bedaquiline 200 mg (2\*100 mg tablets) once daily for 2 weeks followed by 100 mg tablet tiw for 6 weeks with at least 48 hours between doses.
Study: NCT04099329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-game Safety Huddles
Description: Coaches will be trained to lead Pre-game Safety Huddles by the RA with the study using a multi-media tool we have developed. Huddles will be brief (1-2 minutes) and will primarily focused on 1) encouraging concussion reporting and 2) encouraging good sportsmanship
Study: NCT03773146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1X Airtime Incentive
Description: An incentive given in the form of airtime
Study: NCT01768195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir prophylaxis
Description: Entecavir 0.5mg daily from day 1 of immunochemotherapy and/or chemotherapy to 12 months after completing immunochemotherapy and/or chemotherapy.~In patients with low load of hepatitis B virus DNA(≤2000 IU/ml), rituximab will be administrated at the beginning of entecavir prophylaxis. And in patients with high load of hepatitis B virus DNA(\>2000 IU/ml), rituximab will be administrated when hepatitis B virus DNA decreased to the level of 2000 IU/ml after entecavir prophylaxis.
Study: NCT01480310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCAF5352A
Description: may receive up to 3 subcutaneous doses of MCAF5352A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: may receive up to 3 subcutaneous doses of placebo
Study: NCT03592563

Intervention type: BEHAVIORAL
Intervention: Neuro-QoL questionnaire
Description: Follow-up over time will continue (either in-person or over the phone) using the same questionnaires (depending on which group they are belongs to) at approximately 6-month intervals. During each follow-up, participants will be screened for any new signs, symptoms and diagnoses of neurological and/or psychiatric disorders, in order to correlate these outcomes with risk factors captured using the procedures described above.

Intervention type: BEHAVIORAL
Intervention: Neuro-QoL questionnaire
Description: Follow-up over time will continue (either in-person or over the phone) using the same questionnaires (depending on which group they are belongs to) at approximately 6-month intervals. During each follow-up, participants will be screened for any new signs, symptoms and diagnoses of neurological and/or psychiatric disorders, in order to correlate these outcomes with risk factors captured using the procedures described above.

Intervention type: BEHAVIORAL
Intervention: Neuro-QoL questionnaire
Description: Follow-up over time will continue (either in-person or over the phone) using the same questionnaires (depending on which group they are belongs to) at approximately 6-month intervals. During each follow-up, participants will be screened for any new signs, symptoms and diagnoses of neurological and/or psychiatric disorders, in order to correlate these outcomes with risk factors captured using the procedures described above.
Study: NCT03265457

Intervention type: OTHER
Intervention: Specular microscopy
Description: Comparison between corneal Endothelial count in patients with pseudoexfoliation syndrome and age matched group

Intervention type: OTHER
Intervention: Specular microscopy
Description: Comparison between corneal Endothelial count in patients with pseudoexfoliation syndrome and age matched group
Study: NCT01575925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg Oral POM + 40 mg Oral DEX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg Oral POM + 40 mg Oral DEX